Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019693 (
HIV
)
170,526
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Viral replication requires the help of host cell factors, whose species specificity may affect viral tropism. On the other hand, there exist host factors that restrict viral replication. The anti-viral system mediated by some of these restriction factors, which is termed intrinsic immunity and is distinguished from conventional innate and adaptive immunity, has been described as playing an important role in making species-specific barriers against viral infection. Here, we describe the current progress in understanding of such restriction factors against retroviral replication, focusing on
TRIM5alpha
and APOBEC, whose anti-retroviral effects have recently been recognized. Additionally, we mention cyclophilin A, which is essential for
HIV
-1 replication in human cells and may affect viral tropism. Understanding of these host factors would contribute to identification of the determinants for viral tropism.
...
PMID:Host factors involved in resistance to retroviral infection. 1857 67
TRIM5 alpha
is a host protein that can bind to incoming retroviral capsid (CA) and inhibit retroviruses in a species-specific manner. The CA protein of
HIV
-1 also interacts with high affinity to the host protein cyclophilin A (CypA). This binding has been shown to positively affect some early stage of the viral life cycle in human cells. However, the CypA/CA interaction also renders
HIV
-1 more susceptible to rhesus
TRIM5 alpha
(rhTRIM5 alpha) restriction. We find that the ability of old world monkey
TRIM5 alpha
genes to restrict
HIV
-1 in a CypA-dependent manner is widespread. On the other hand, we find that simian immunodeficiency viruses from tantalus monkeys (SIVagmTAN), is unlike
HIV
-1 in that CypA does not enhance the rhTRIM5 alpha restriction against the virus even though the CA of this virus, like
HIV
-1, does bind CypA. Mapping of the determinants for this phenotype by swapping regions on CA between SIVagmTAN and
HIV
-1 showed that when SIVagmTAN contains loops between helices 4/5 (4-5 loop) and 6/7 (6-7 loop) from
HIV
-1 CA, it becomes susceptible to the CypA-enhanced rhTRIM5 alpha restriction. Surprisingly, when SIVagmTAN contains either loop from
HIV
-1 CA, it gains sensitivity to
TRIM5 alpha
from species which originally have no effect on the wild-type virus. Moreover, we find that CypA/CA interaction occurs early after viral entry but the CypA-enhanced restriction mostly acts on the stage after reverse transcription.
...
PMID:Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1. 1867 85
Rhesus macaques are resistant to infection by
HIV
-1 as a result of an innate cellular restriction mechanism attributable to the expression of rhTRIM5alpha, a member of the large tripartite motif (TRIM) protein family.
TRIM5alpha
-mediated restriction, which occurs before reverse transcription through targeting of the
HIV
-1 capsid, has been identified in a number of macaque primary cells and cell lines and is thought to occur in all macaque cell types. We report, however, that rhesus macaque dendritic cells (DCs) lack
TRIM5alpha
-mediated restriction and are equally permissive to
HIV
-1 infection as human DCs. Evidence suggests that, although
TRIM5alpha
RNA levels are normal in these cells, the protein may be dysfunctional. We propose that abrogation of
TRIM5alpha
-mediated restriction in DCs, although still operative in cells that replicate
HIV
-1 (macrophages, T lymphocytes), illustrates the need for innate mechanisms to not inhibit adaptive immune responses to ensure an optimal fight against pathogens.
...
PMID:Lack of endogenous TRIM5alpha-mediated restriction in rhesus macaque dendritic cells. 1870 3
The rhesus monkey intrinsic immunity factor
TRIM5alpha
(rh) recognizes incoming capsids from a variety of retroviruses, including human immunodeficiency virus type 1 (HIV-1) and equine infectious anemia virus (EIAV), and inhibits the accumulation of viral reverse transcripts. However, direct interactions between restricting
TRIM5alpha
proteins and retroviral capsids have not previously been demonstrated using pure recombinant proteins. To facilitate structural and mechanistic studies of retroviral restriction, we have developed methods for expressing and purifying an active chimeric
TRIM5alpha
(rh) protein containing the RING domain from the related human TRIM21 protein. This recombinant TRIM5-21R protein was expressed in SF-21 insect cells and purified through three chromatographic steps. Two distinct TRIM5-21R species were purified and shown to correspond to monomers and dimers, as analyzed by analytical ultracentrifugation. Chemically cross-linked recombinant TRIM5-21R dimers and mammalian-expressed TRIM5-21R and
TRIM5alpha
proteins exhibited similar sodium dodecyl sulfate-polyacrylamide gel electrophoresis mobilities, indicating that mammalian
TRIM5alpha
proteins are predominantly dimeric. Purified TRIM5-21R had ubiquitin ligase activity and could autoubquitylate with different E2 ubiquitin conjugating enzymes in vitro. TRIM5-21R bound directly to synthetic capsids composed of recombinant
HIV
-1 CA-NC proteins and to authentic EIAV core particles.
HIV
-1 CA-NC assemblies bound dimeric TRIM5-21R better than either monomeric TRIM5-21R or TRIM5-21R constructs that lacked the SPRY domain or its V1 loop. Thus, our studies indicate that
TRIM5alpha
proteins are dimeric ubiquitin E3 ligases that recognize retroviral capsids through direct interactions mediated by the SPRY domain and demonstrate that these activities can be recapitulated in vitro using pure recombinant proteins.
...
PMID:Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. 1879 73
Pathogenic viral infections have exerted selection pressure on their hosts to evolve cellular antiviral inhibitors referred to as restriction factors. Examples of such molecules are APOBEC3G, APOBEC3F and
TRIM5alpha
. APOBEC3G and APOBEC3F are cytidine deaminases that are able to strongly inhibit retroviral replication by at least two mechanisms. They are counteracted by the lentiviral Vif protein.
TRIM5alpha
binds to sensitive, incoming retroviruses via its C-terminal PRY/SPRY domain and rapidly recruits them to the proteasome before significant viral DNA synthesis can occur. Both of these proteins robustly block retroviral replication in a species-specific way. It remains an open but important question as to whether innate restriction factors such as these can be harnessed to inhibit
HIV
-1 replication in humans.
...
PMID:Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. 1897 20
We have recently generated a monkey cell-tropic virus termed NL-DT5R from an
HIV
-1 NL4-3 clone and demonstrated that both cyclophilin A (CypA)-binding loop in Gag-capsid (CA) and Vif are responsible for the species-restriction of
HIV
-1. In this study, we constructed 16 CypA-binding loop mutants from the
HIV
-1-derivative NL-DT5R, and analyzed them biologically and biochemically. The mutants displayed various multi-cycle infection potencies in cynomolgus monkey (CyM) HSC-F cells, but none of them grew significantly better than NL-DT5R. Consistently, any of the
HIV
-1 variants examined here did not effectively counter CyM
TRIM5alpha
as judged by single-cycle infectivity assays. Assessment of their single-cycle infectivity in simian and CyM
TRIM5alpha
-expressing feline cells in the presence of cyclosporin A (CsA) showed that intervention of CypA-CA interaction did not restore full NL-DT5R infectivity, while CsA increased infectivity of DT5R/4-3 carrying the sequence of NL4-3 CypA-binding loop up to the NL-DT5R level. Almost similar data were obtained in the experiments utilizing CypA-targeting siRNA. Together with our previous results regarding NL-DT5R, these data suggested that evasion from CypA- and APOBEC-mediated restrictions is still insufficient for
HIV
-1 to completely overcome the species barrier.
...
PMID:Evasion from CypA- and APOBEC-mediated restrictions is insufficient for HIV-1 to efficiently grow in simian cells. 1905 9
In 2004, the first report of
TRIM5alpha
as a cellular antiretroviral factor triggered intense interest among virologists, particularly because some primate orthologs of
TRIM5alpha
have activity against
HIV
. Since that time, a complex and eventful evolutionary history of the TRIM5 locus has emerged. A review of the TRIM5 literature constitutes a veritable compendium of evolutionary phenomena, including elevated rates of nonsynonymous substitution, divergence in subdomains due to short insertions and deletions, expansions and contractions in gene copy number, pseudogenization, balanced polymorphism, trans-species polymorphism, convergent evolution, and the acquisition of new domains by exon capture. Unlike most genes, whose history is dominated by long periods of purifying selection interspersed with rare instances of genetic innovation, analysis of restriction factor loci is likely to be complicated by the unpredictable and more-or-less constant influence of positive selection. In this regard, the molecular evolution and population genetics of restriction factor loci most closely resemble patterns that have been documented for immunity genes, such as class I and II MHC genes, whose products interact directly with microbial targets. While the antiretroviral activity encoded by TRIM5 provides plausible mechanistic hypotheses for these unusual evolutionary observations, evolutionary analyses have reciprocated by providing significant insights into the structure and function of the
TRIM5alpha
protein. Many of the lessons learned from TRIM5 should be applicable to the study of other restriction factor loci, and molecular evolutionary analysis could facilitate the discovery of new antiviral factors, particularly among the many TRIM genes whose functions remain as yet unidentified.
...
PMID:Molecular evolution of the antiretroviral TRIM5 gene. 1923 38
Variable region 1 (V1) of the SPRY domain of
TRIM5alpha
is a major determinant for species-specific virus restriction in primates. We previously reported that a chimeric
TRIM5alpha
containing baboon V1 in the background of cynomolgus monkey
TRIM5alpha
showed potent anti-human immunodeficiency virus type 2 (HIV-2) activity. Since baboons are reportedly sensitive to HIV-2 infection, there was a discrepancy between the ability of baboon
TRIM5alpha
V1 to restrict
HIV
-2 and baboon sensitivity to
HIV
-2. In the study presented here, we examined the roles of V2 and V3 of the baboon
TRIM5alpha
SPRY domain in its anti-
HIV
-2 activity. A chimeric
TRIM5alpha
containing the entire baboon SPRY domain showed weak anti-
HIV
-2 activity. This attenuation of activity was caused by a single serine-to-proline substitution in baboon
TRIM5alpha
V2. These findings indicate that the combination of V1 with other variable regions of SPRY is important in anti-
HIV
-2 activity of primate
TRIM5alpha
.
...
PMID:Impact of a single amino acid in the variable region 2 of the Old World monkey TRIM5alpha SPRY (B30.2) domain on anti-human immunodeficiency virus type 2 activity. 1934 71
The global acquired immunodeficiency syndrome (AIDS) pandemic is thought to have arisen by the transmission of human immunodeficiency virus (
HIV
-1)-like viruses from chimpanzees in southeastern Cameroon to humans.
TRIM5alpha
is a restriction factor that can decrease the susceptibility of cells of particular mammalian species to retrovirus infection. A survey of TRIM5 genes in 127 indigenous individuals from southeastern Cameroon revealed that approximately 4% of the Baka pygmies studied were heterozygous for a rare variant with a stop codon in exon 8. The predicted product of this allele, TRIM5 R332X, is truncated in the functionally important B30.2(SPRY) domain, does not restrict retrovirus infection, and acts as a dominant-negative inhibitor of wild-type human
TRIM5alpha
. Thus, some indigenous African forest dwellers potentially exhibit diminished
TRIM5alpha
function; such genetic factors, along with the high frequency of exposure to chimpanzee body fluids, may have predisposed to the initial cross-species transmission of
HIV
-1-like viruses.
...
PMID:A rare null allele potentially encoding a dominant-negative TRIM5alpha protein in Baka pygmies. 1957 66
Human immunodeficiency virus type 1 (HIV-1) vectors transduce rhesus blood cells poorly due to a species-specific block by
TRIM5alpha
and APOBEC3G, which target
HIV
-1 capsid and viral infectivity factor (Vif), respectively. We sought to develop a lentiviral vector capable of transducing both human and rhesus blood cells by combining components of both
HIV
-1 and simian immunodeficiency virus (SIV), including SIV capsid (sCA) and SIV Vif. A chimeric
HIV
-1 vector including sCA (chiHIV) was superior to the conventional SIV in transducing a human blood cell line and superior to the conventional
HIV
-1 vector in transducing a rhesus blood cell line. Among human CD34(+) hematopoietic stem cells (HSCs), the chiHIV and
HIV
-1 vectors showed similar transduction efficiencies; in rhesus CD34(+) HSCs, the chiHIV vector yielded superior transduction rates. In in vivo competitive repopulation experiments with two rhesus macaques, the chiHIV vector demonstrated superior marking levels over the conventional
HIV
-1 vector in all blood lineages (first rhesus, 15 to 30% versus 1 to 5%; second rhesus, 7 to 15% versus 0.5 to 2%, respectively) 3 to 7 months postinfusion. In summary, we have developed an
HIV
-1-based lentiviral vector system that should allow comprehensive preclinical testing of
HIV
-1-based therapeutic vectors in the rhesus macaque model with eventual clinical application.
...
PMID:Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. 1962 95
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>